Audit: QRS - Lactobacillus rhamnosus for Health & Longevity
Audit conducted on 06/09/2026 03:28 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: protocol values (ER 354, 360, 364), time-to-effect (ER 379, 403, 429), benefit/risk tier headings (ER 149-229, 251-295), contraindications (ER 329-334), interactions (ER 313-325), biomarker table (ER 431-438), qualitative list (ER 442-446). All literally supported. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious ER phrasing carried through, e.g. “no pharmacological interaction” (ER 319) and “No established target; individual’s own baseline” (ER 438). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No tier, threshold, or gate is up- or down-graded; “Absolute contraindication in most protocols” (ER 317) is rendered as a hard [stop_items] entry, not a caution. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come from the ER’s “Populations who should avoid” list, interactions from the ER interaction bullets, risks from Potential Risks & Side Effects. No cross-category migration. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, study names, author names, NCT identifiers, or brand names appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No named person, institution, or organisation is credited anywhere in the QRS. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s sober, deflationary register (“Results do not transfer between products”, “Nothing in the human record speaks to lifespan”). |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert and data-driven (explicit CFU ranges, biomarker targets) while remaining readable; the strain-specificity caveat is stated plainly enough to act on. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents thresholds and gates as evidence, with no clinician-style directives. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative or prescriptive constructions; the footer disclaimer is the template’s fixed text. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Fields state what protocols and trials used, not what should be done. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the file (verified by search for you/your/yours/yourself). |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language throughout; the only technical terms retained are biomarker names and severity classes that item 4.3 and item 8.5 require to be kept exact. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | All fields are short noun phrases or single clauses; no field exceeds one sentence plus a sub-line. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no direct address anywhere in the QRS. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Content is framed for a proactive optimiser: dose range, timing, monitoring cadence, and the explicit note that the adult signal is weaker. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Protocol assumes willingness to follow trial-matched dosing, meal timing, and an eight-to-twelve-week monitoring panel. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No simplification for a casual reader; biomarker targets and severity classes are retained. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | [at_a_glance] explicitly separates the paediatric signal from the adult one and states that nothing in the human record speaks to lifespan — exactly the divergence relevant to this audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not appear; the header frames the topic as “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal register throughout (“colony-forming units”, “erythrocyte sedimentation rate”, “infective endocarditis”); no consumer-grade substitutes. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed strings verified against the template: “Protocol” (571 in template / line 440), “Time to effect” (477), “Benefits” (519), “Risk & Side Effects” (571), “Monitoring” (590), “Qualitative Assessment” (676), “Contraindications” (539), “Key Interactions” (553), tier labels High/Medium/Low/Speculative, and Marker/Target/Why headers (594-596). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All template variable spans are present: 57 data-qrs-var spans, matching the template’s 34 single-instance vars plus 6 marker rows (18) and 5 qualitative items. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The non-checklist spans are untouched: website="evidence_review", website="audit", and website="full_review" all retain their template values. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | N/A — no source ER section relied on by the QRS is empty; every mapped ER section has content. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | ER bold labels reproduced verbatim: “Standard dose”, “Best time of day”, “Single versus split dosing” (ER 354, 360, 364) and all six interaction labels including their parenthetical drug lists (ER 313-325). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No label is invented; the time-to-effect labels (“Antibiotic-associated diarrhea”, “Mood and metabolic endpoints”, “Inflammatory markers”) are literal ER phrases from lines 403 and 429, and all six biomarker names are verbatim from the ER table. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters anywhere in the file; the ER’s 🟩/🟥/🟨/⚠️ markers were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Per-section budgets are respected — 7 contraindications, 6 interactions, 4 benefit lines, 4 risk lines, 6 biomarker rows, 5 qualitative items, all at 9-9.5pt within the template’s single-sheet layout. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | The metadata comment opens on line 2, immediately after <!doctype html> on line 1, and precedes all other content. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- on line 3, closing --- on line 13; the preceding “QRS — Metadata (invisible, parsed by audit tooling)” text sits before the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | The block is inside an HTML comment and nothing on the sheet reproduces it. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; the only quoted value is duration: "00:03", which requires quoting because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: lactobacillus_rhamnosus_2026-0906-0002_Opus_ER.md (line 4) matches the source ER. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.7.02 (line 5) matches the version badge at the top of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0906-0300 (line 6) is well-formed YYYY-MMDD-HHMM. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus (line 7). |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5 (line 8). |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version number with no additional qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: lactobacillus_rhamnosus_2026-0906-0002_Opus_QRS.html (line 9) matches the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified — no stray whitespace or unnecessary quoting on any of the nine frontmatter values. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | <title> reads “Lactobacillus rhamnosus for Health & Longevity - Quick Reference Sheet” — canonical_topic (ER frontmatter line 8) with the ampersand entity-encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | [header_topic] (line 417) reads “Lactobacillus rhamnosus for Health & Longevity”, correctly entity-encoded. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | qrs_creation_date 2026-0906-0300 renders as “09/06/2026” (line 421), correct MM/DD/YYYY. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | [header_subline_model] reads “Opus 5” (line 425), matching qrs_creator_ai_fullname. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header carries only the title and the template’s fixed subline; no badge, AKA line, version stamp, or variant marker. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the ER Conclusion (ER 468-472) into the decision-relevant core: what is firmest, in whom, non-transferability between products, the safety split, and the absence of lifespan data. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 54 words — within the 60-word cap. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct ER Conclusion passage: “live gut bacterium … long clinical record” (ER 468), “firmest findings … adult signal is weaker” (ER 468), “results do not transfer between products” (ER 472), “safety picture is favorable … serious for those whose are not” (ER 470), “Nothing in the human record speaks to lifespan” (ER 470). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms or specialist classifications; uses “gut bacterium”, “antibiotic-caused loose stools”, “airway infections”, “defenses”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes, or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No relative risks, odds ratios, confidence intervals, or absolute risk figures. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All seven items trace to the ER Key Interactions & Contraindications section (ER 317 and 329-334). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | The ER’s six “Populations who should avoid” bullets are all represented; the first is split into immunosuppressive therapy and neutrophil count as separate gates, and the drug list is taken from ER 317. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | All seven items are discrete <li> elements inside the [stop_items] span (lines 542-548). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Each item is a bare noun phrase; no rationale, mechanism, citation, or trailing dash clause survives. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Decision-bearing qualifiers preserved: “below 0.5 × 10⁹/L”, “(Mayo endoscopic subscore 3)”, and the immunosuppressant drug list “(tacrolimus, ciclosporin, high-dose corticosteroids, biologics)”. The only dropped parenthetical, “(infection of the heart’s inner lining or valves)”, is a glossary definition rather than a qualifier that changes applicability, and item 8.4 requires such elaborations to be stripped. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | N/A — the ER’s Key Interactions & Contraindications section uses no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Not applicable as an exemption — the ER names six populations that should avoid the intervention and the section is correctly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | N/A — the section is not empty; seven [stop_items] are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All six items trace to the ER interaction bullets at ER 313-325. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All seven ER interaction bullets are represented except Immunosuppressants, which is correctly excluded because it is carried as a contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | All six items are discrete <li> elements inside the [caution_items] span (lines 556-561). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Each item reduces to the ER’s own verdict word or phrase (“timing matters”, “monitor”, “no pharmacological interaction”, “potentiating”, “additive”, “timing”); all mechanistic follow-on sentences are stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every ER example drug list is preserved intact: “(amoxicillin, clarithromycin, ciprofloxacin)”, “(fluconazole, nystatin)”, “(omeprazole, famotidine)”, “(prebiotic fibers, other probiotic strains)”, “(fecal microbiota transplantation, colonoscopy preparation)”. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | N/A — the ER’s Key Interactions & Contraindications section uses no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Not applicable as an exemption — the ER names seven interactions and the section is correctly populated rather than empty. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | N/A — the section is not empty; six [caution_items] are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three action sets derive from the ER Therapeutic Protocol section (ER 354, 360, 364). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, administration timing, and dosing frequency are the three actionable levers in the ER Protocol section; the remaining bullets (approach philosophy, origin, persistence, polymorphisms, sex, age, baseline biomarkers, pre-existing conditions) are contextual rather than actionable. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | N/A — the ER Therapeutic Protocol section supplies three or more distinct actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action fields carry ER-derived content; no placeholder or empty-state text remains. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Covers the two aspects in the ER Practical Considerations “Time to effect” bullet (ER 403) plus the inflammatory-marker interval from ER 429 (“the shortest interval over which trials detected change”). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered by benefit tier: antibiotic-associated diarrhea (ER High), mood and metabolic endpoints (ER Medium), inflammatory markers (ER Low). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | N/A — the ER supplies three distinct time-to-effect aspects; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time fields carry ER-derived content; the subs quote ER 379, ER 403, and ER 429 respectively. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | N/A — the ER provides time-to-effect information (Practical Considerations line 403 and Monitoring Protocol line 429). |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All four tiers mirror the ER Expected Benefits sub-section headings (ER 149-229). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four variables are present and populated (lines 521-532). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a semicolon-separated list of condensed ER benefit headings with no effect sizes, mechanisms, or study detail. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefits item; the ER’s magnitude lines and ⚠️ Conflicted markers are stripped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | N/A — all four benefit tiers have items in the ER Expected Benefits section; none is empty. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All four tiers mirror the ER Potential Risks & Side Effects sub-section headings (ER 251-295). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four variables are present and populated (lines 573-584). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a condensed list of ER risk headings; no frequencies, odds ratios, or mechanistic detail carried over. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any risks item; the ER magnitude lines and ⚠️ Conflicted marker are stripped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | N/A — all four risk tiers have items in the ER Potential Risks & Side Effects section; none is empty. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | All six rows derive from the ER Monitoring Protocol & Defining Success biomarker table (ER 431-438). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All six ER table rows are present with matching targets: hs-CRP below 1.0 mg/L, fecal calprotectin below 50 µg/g, neutrophils above 1.5 × 10⁹/L, HbA1c 4.8-5.4%, ESR below 15 mm/hr men / 20 women, fecal sIgA no established target. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | [monitoring_cadence] (line 670) condenses ER 429: baseline panel, eight-to-twelve-week recheck, six-to-twelve-month intervals, and blood cultures on unexplained fever. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All five items derive from the ER qualitative-marker list at ER 442-446. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five ER qualitative markers are present: bowel habit, post-meal bloating and gas, upper-respiratory episode frequency and duration, perceived stress and mood stability, and digestive tolerance of an antibiotic course. |
Issues 06/09/2026 03:28
Pass rate 100.00%. No issues found.
Issues 06/09/2026 03:22
- 2.5 — Monitoring “Why” cell gives instruction: [marker_5_why] at line 652 reads “Slower-moving marker; use if deep-seated infection suspected”, turning the ER’s descriptive “useful when a deep-seated infection is suspected” (ER line 437) into an instruction to the reader.
Fixes 06/09/2026 03:22
- 2.5 — Monitoring “Why” cell instruction: Changed [marker_5_why] from “Slower-moving marker; use if deep-seated infection suspected” to “Slower-moving marker; useful when deep-seated infection is suspected”, restoring the ER’s descriptive phrasing.
Issues 06/09/2026 03:16
- 1.2 / 1.3 — Lifespan claim overstated: [at_a_glance] (line 433) says “Nothing speaks to lifespan”, dropping the ER Conclusion’s scoping “in the human record” (ER line 470); the QRS itself lists “Lifespan extension” as a Speculative benefit, so the unqualified form contradicts its own Benefits card.
- 1.3 — Antifungal interaction overstated: [caution_items] (line 558) reduces the ER’s “No pharmacological interaction” (ER line 319) to “no interaction”, broadening a scoped claim.
- 2.6 / 2.9 — Marker target addresses reader: [marker_6_target] (line 660) reads “No established target; track own baseline”, an unattached imperative directed at the reader; the ER (line 438) writes “track change from the individual’s own baseline”.
- 11.4 — Time-to-effect sub duplicates value: [time_1_sub] (line 489) “Protection applies from the first days.” restates [time_1_value] (line 486) “First days of the course” and carries no additional ER content.
Fixes 06/09/2026 03:16
- 1.2 / 1.3 — Lifespan claim rescoped: Changed [at_a_glance] from “Nothing speaks to lifespan.” to “Nothing in the human record speaks to lifespan.”, restoring the ER Conclusion’s scoping clause (at-a-glance now 53 words, within the 60-word budget).
- 1.3 — Antifungal interaction rescoped: Changed the antifungals [caution_items] entry from “no interaction” to “no pharmacological interaction”, matching the ER’s scoped wording.
- 2.6 / 2.9 — Marker target no longer imperative: Changed [marker_6_target] from “No established target; track own baseline” to “No established target; individual’s own baseline”, removing the imperative directed at the reader.
- 11.4 — Time-to-effect sub made substantive: Replaced [time_1_sub] “Protection applies from the first days.” with “Trial windows spanned the course plus a week.”, drawn from the ER’s Discontinuation & Cycling section, so the sub no longer restates the value.
Issues 06/09/2026 03:07
- 4.5 — Sheet overruns one A4 page: Un-condensed fields push the estimated rendered height to roughly 1.7 A4 pages — [action_2_sub] (137 chars, QRS line 461) and [action_3_sub] (148 chars, QRS line 472) carry near-verbatim ER sentences into one-third-width cells, [monitoring_cadence] (230 chars, QRS line 669) reproduces ER line 429 almost intact, [marker_6_target] (QRS line 659) is a 70-char ER phrase, [at_a_glance] runs five rendered lines at 16px, and the first contraindication plus the
Lowbenefits row wrap to three and two lines respectively.
Fixes 06/09/2026 03:07
- 4.5 — Protocol sub-cells condensed: Trimmed [action_1_sub] (107→57 chars), [action_2_sub] (137→71) and [action_3_sub] (148→64) from near-verbatim ER sentences to the load-bearing fact, cutting the protocol row from four rendered lines to two.
- 4.5 — Time-to-effect sub-cells condensed: Shortened [time_1_sub], [time_2_sub] and [time_3_sub] (e.g. “Trials ran three to six months before measuring, so shorter trials are uninformative” → “Shorter trials are uninformative”), removing wording already carried by the adjacent value cell.
- 4.5 — At-A-Glance tightened: Reduced [at_a_glance] from 58 to 51 words by folding the population caveat into an em-dash clause and dropping “in the human record”.
- 4.5 — Monitoring cadence condensed: Replaced the near-verbatim ER sentence in [monitoring_cadence] (230→166 chars) with the schedule and the fever trigger only.
- 4.5 — Monitoring cells shortened: Trimmed [marker_1_why], [marker_2_why], [marker_3_why], [marker_4_why], [marker_5_target], [marker_5_why], [marker_6_target] and [marker_6_why] so each fits its column, while keeping every marker, target and rationale from the ER table.
- 4.5 — Decision-gate items shortened: Split the combined immunosuppression/neutrophil contraindication into two shorter items and trimmed the remaining [stop_items] and the trailing verdicts in [caution_items]; all thresholds, staging and example-drug parentheticals were preserved and the ER bold labels left verbatim.
- 4.5 — Low benefits row shortened: Condensed [benefits_low] (194→155 chars) to the five ER benefit names without their trailing population qualifiers.
- 4.5 — Qualitative items shortened: Trimmed [qualitative_item_1], [qualitative_item_3] and [qualitative_item_5] so each renders on a single line.